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ABSTRACT 
Present-day nuclear receptors (NRs) responding to adrenal and sex steroids are key 
regulators of reproduction and growth in mammals, and are thought to have evolved from an 
ancestral NR most closely related to extant estrogen-related receptors (ERRs). The molecular 
events (and ligands) that distinguish steroid-activated NRs (SRs) from their inferred ancestor, 
that gave rise to both the ERRs and SRs, remain unknown. We report that target sequences 
for fatty-acylation (palmitoylation) at a key cysteine residue (corresponding to Cys447 in 
human estrogen receptor ERα) in helix 8 of the ligand-binding domain accurately demarcate 
SRs from ERRs. Docking studies are consistent with the hypothesis that palmitate embeds 
into a key groove in the receptor surface. The implications of lipidation, and of potential 
alternative ligands for the key cysteine residue, for receptor function and the evolution of SRs 
are discussed. 
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Highlights 
 
The key structural changes underlying the transition from ERRs to vertebrate SRs are not 
known. 
 
Extant SRs, exemplified by ERα, contain a site for cysteine fatty-acylation (principally 
palmitate) that is reported to promote both membrane association and receptor activity.  
 
Comparative sequence analysis reveals that the fatty-acylation motif is present in SRs but is 
absent from all ERRs. 
 
Molecular modeling indicates that palmitate locates to a groove in the surface of the ligand-
binding domain, at a site that may modulate the 3D structure of the receptor. 
 
Other potential interactions with the key cysteine residue include second-site steroid ligand 
and metalloestrogen binding. 
 
Because the fatty-acylation sequence accurately demarcates SRs from ERRs, this modification 
may have played a role in the emergence of vertebrate receptors responding to steroids. 
 
1. Introduction 
Nuclear receptors (NRs) responding to adrenal and sex steroids in mammals orchestrate a 
spectrum of physiological processes including growth, immunity and inflammation, 
reproduction, stress, and water/salt homeostasis. All extant NRs comprise an N-terminal 
domain (NTD) and a DNA-binding domain (DBD), that are fused via a linker to a C-terminal 
ligand/hormone-binding domain [1]. The structure of the DBD is substantially conserved 
across all NRs, and we focus here on the ligand-binding domain and the ligands that bind to 
this module and activate transcription via binding of the receptor to specific DNA sequences. 
The ancestral ligand for the first NRs in general could have been a 5-carbon terpenoid or a 
long-chain fatty acid [2;3], and studies on a remote species that contains only two NR 
polypeptides (Amphimedon queenslandia, a sponge) revealed that both NR1 and NR2 bind 
long-chain fatty acids. Interestingly, liganded NR1 activated transcription while liganded NR2 
inhibited transcription [3]. Trichloplax, a simple multicellular animal at the base of metazoans, 
has been found to have orthologs of only four nuclear receptors – ERR, retinoid X receptor 
(RXR), COUP, and HNF4, but lacks conventional steroid receptors [4;5]. Early radiation of this 
group of receptors by gene duplication and mutation then generated other NRs. 
Around 500 million years ago a sea-change took place in NR signaling with the evolution of 
the first receptors that responded to vertebrate steroids.  This step was characterized by (i) 
the emergence of steroids, defined as molecules that lack all (or most of) the characteristic 
long hydrophobic sidechain of cholesterol – an oxidative reaction now catalyzed by the 
P450scc (sidechain cleavage; scc) enzyme – and (ii) the (co)evolution of the first vertebrate 
steroid NRs that that respond to sub-nanomolar concentrations of these more compact 
steroids.  
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The weight of evidence argues that vertebrate steroid-type NRs derive from an ancestral 
polypeptide that was most closely related to ERs [6-10], and elegant work has been done to 
reconstruct the ancestral receptor [10;11]. This ancestral ER-like receptor is presumed to 
have later diversified through gene duplication and mutation to generate the extant steroid 
receptors including ERα and ERα, as well as a steroid receptor that was the ancestor of the 
androgen, glucocorticoid, mineralocorticoid, and progesterone receptors (AR, GR, MR, PR) 
that respond to 3-ketosteroids. However, the key changes that precipitated the evolution of 
steroid-activated vertebrate receptors and the identities of their ancestral ligands (if any) 
remain unknown. A reconstructed ancestral SR appears to have had only low affinity for 
estradiol (E2), and potential ligands such as an aromatized cholesterol derivative have been 
suggested [10;11]; however, the full spectrum of other potential ligands has not yet been 
tested.  
In the text the term AncSR is used to describe the common ancestor of the class of 
vertebrate receptors that first responded to steroid (or similar) ligands; this polypeptide 
corresponds to AncSR1 as defined by Thornton et al. [7;11] and to AncSR of Markov et al. 
[12]. The term AncERR is used to describe the earlier common ancestor that gave rise to the 
ERR class of receptors as well as to AncSR, and later to the vertebrate steroid receptors. 
Traditional nomenclature with Greek symbols (e.g., ERα) is employed to denote particular 
receptor types; however, to avoid the use of Greek symbols in computer analysis, in figures 
and when referring to a specific sequence entry the HUGO gene/protein guidelines (e.g., 
ESR1 for ERα) are followed.  
In the following we focus on the structure and function of the ligand-binding domains of 
these receptors. We make a distinction between (i) the C-terminal module that responds to 
ligand, and (ii) the specific subregion, the ligand-binding pocket (LBP), that interacts directly 
with bound ligand.  
1.1. The key changes accompanying ERR to SR evolution may be outside the LBP 
Greschik and colleagues mutated key residues in the LBPs of the human ERRγ (ESRRG) and 
ERRα (ESRRA) to correspond to those found in ERα (ESR1), but this did not generate a high-
affinity receptor responding to E2 [13;14]. Structural comparisons and sequence alignments 
of ERR ligand-binding domains versus ERα (e.g., [13;15;16], and supplementary data online) 
provide no evidence for major insertions or deletions. There is an insertion of eight residues 
between helices 8 and 9 in ERs that distinguishes ERs from ERRs (but this insertion is not 
present in AR, GR, MR, or PR), and also a three residue insertion between helices 9 and 10 
could potentially be important (Figure S3 in the Supplementary Material Online). 
We focused on helix 8 (H8) of the ligand-binding domain because (i) the H8–9 loop differs 
significantly between ERRα and ERα [14], (ii) mutation of Cys447 in H8 of ERα is reported to 
depress E2-mediated transcription activation by a large margin [17], and, importantly, as 
discussed below, (iii) this specific residue has been implicated in the covalent addition of 
long-chain fatty acids, the primary focus of this paper. 
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1.2. Covalent fatty-acylation of mammalian steroid receptors 
Protein modification by covalent addition of long-chain fatty acids, principally palmitate, is 
conserved between yeast and mammals [18]. The modification is dynamic, and proteins can 
undergo multiple rounds of palmitoylation and depalmitoylation [19;20]. Human ERα 
contains a key cysteine residue within H8 of the ligand-binding domain, at a site distal from 
the hormone-binding site (LBP), which serves as an attachment site for a covalently bound 
palmitate chain [21]. A specific 9 amino acid motif surrounding the cysteine residue has been 
implicated in palmitoylation of human ERα, ERβ, PR, and AR [22]. All these NRs contain a 
sequence EFVCLKSII or close relative (the target cysteine is underlined); palmitoylation at 
this site (and consequent membrane binding) is thought to facilitate interactions with other 
membrane-bound proteins and promote fast non-genomic signaling ('membrane-initiated 
steroid signals' – MISS [1]). 
Lipidation may also directly modulate receptor activity – mutation of the target residue 
Cys447 in human ERα, expressed in mammalian CHO cells, led to a 50-fold reduction in 
transactivation by E2, whereas mutation of other cysteine residues had no effect [17]. 
Moreover, in female mice, homozygous replacement of the corresponding cysteine residue 
in mouse ERα (Cys451) by Ala led to complete infertility and depressed E2-mediated gene 
expression ([23;24]; [1] for review). This evidence for the importance of the lipidation target 
site in H8 of ERα raises the question of whether this modification appeared early in the 
evolution of vertebrate steroid-activated NRs, and whether it could have played a role in ERR 
to ER evolution. We therefore studied the evolutionary history of palmitoylation in ERRs and 
ERs. We report that the lipidation target sequence accurately demarcates ERs and other SRs 
from ERRs, and we discuss the structural and functional implications for steroid receptor 
evolution. 
2. Methods 
2.1 Sequence and phylogenetic analysis 
Sequences were drawn from publicly available databases including NCBI 
(https://www.ncbi.nlm.nih.gov/protein/), UniProt (http://www.uniprot.org/), and the Joint 
Genome Institute Genome Portal (https://genome.jgi.doe.gov/portal/). Sequence 
comparisons employed pBLAST searching (https://blast.ncbi.nlm.nih.gov/Blast.cgi); 
alignments were constructed using Clustal Omega [25] 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) and displayed using mView 
(www.ebi.ac.uk/Tools/msa/mview/) using the color setting 'Any'. For phylogenetic analysis, 
trees were constructed using PhyML 3.0 [26] (http://www.atgc-montpellier.fr/phyml), and 
tree drawing employed FigTree (http://tree.bio.ed.ac.uk/software/figtree). Prediction of 
palmitoylation sites employed GPS-Lipid [27] (http://lipid.biocuckoo.org/webserver.php) and 
CSS-Palm [28] (http://csspalm.biocuckoo.org/online.php). 
2.2. Structural modeling and molecular dynamics 
Using the Build functions in PyMol 1.8.6.2 [29], the structure of the ERα ligand-binding 
domain (PDB 1A52; see [30;31]) was manually palmitoylated on Cys447, and a NAMD 
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topology was generated using the psfgen plugin of VMD 1.9.3 [32].  It was then solvated and 
neutralized by the addition of TIP3P water molecules [33] and Na+ and Cl− ions (to a 
concentration of 150 mM) to form a 108 Å × 108 Å × 108 Å simulation box. The full system 
comprised 115 689 atoms. NAMD 2.12 [34] was used for simulating this system, using the 
CHARMM36 force field [35] in a Langevin temperature and pressure controlled (NPT @ 
310K) ensemble with periodic boundary conditions and particle-mesh Ewald electrostatics. 
Following energy minimization to remove van der Waals clashes within the system, a 
production run of 300 ns was performed. The Cα RMSD between starting structure and final 
frame of the simulation was 2.36 Å. 
2.3. Docking studies 
E2 was docked into the ERα ligand-binding domain (PDB 1A52) using Autodock. First, water 
molecules and other heteroatoms were removed from the structure, and the program 
PDB2PQR 2.1.1 [36] used to assign position-optimized hydrogen atoms, utilizing the 
additional PropKa2 algorithm [37] with a pH of 7.4 to predict protonation states. The 
MGLTools 1.5.6 [38] utility prepare_receptor4.py was used to assign Gasteiger charges to 
atoms. Hydrogen atoms were assigned to compound structures using OpenBabel 2.4.1 [39], 
utilizing the -p option to predict the protonation states of functional groups at pH 7.4. The 
MGLTools utility prepare_ligand4.py was used to assign Gasteiger charges and rotatable 
bonds. Autodock 4.2.6 [40] was used to automatically dock the compounds into the second 
ligand-binding site of the crystal structures. A grid box that encompassed the maximum 
dimensions of the ligand plus 12 Å in each direction was used. The starting translation and 
orientation of the ligand and the torsion angles of all rotatable bonds were set to random. 
The Autogrid grid point spacing was set at 0.2 Å. The Autodock parameter file specified 50 
Lamarckian genetic algorithm runs, 15 000 000 energy evaluations, and a population size of 
300.  
3. Results 
3.1. Lipidation sequences demarcate steroid receptors from precursors 
We analyzed the ligand-binding domains of ERRs and steroid-type NRs in the vertebrate 
lineage (receptors and accessions are listed in Table S1 in the supplementary material 
online). As shown in Figure 1, none of the vertebrate ERR ligand-binding domains contain the 
target cysteine residue for palmitoylation, whereas (with some exceptions, discussed below) 
all vertebrate steroid NRs harbor a highly conserved sequence containing the key cysteine 
residue for lipidation. For example, in amphioxus (Branchiostoma floridae), that radiated 
shortly before the emergence of the vertebrates, the ER contains the sequence EYLCLKAIT, 
whereas the equivalent sequence in amphioxus ERR, EFVVLKAMA, lacks the key cysteine 
residue (Figure 1; detailed alignments are presented in Figures S2,S3). More divergent ERR-
related sequences in fruitfly (Drosophila melanogaster), sea squirt (Ciona intestinalis), and 
sea urchin (Strongylocentrotus purpuratus) lack the key cysteine residue (Figure 2); this motif 
is also absent from all steroid receptor-related sequences studied from annelids, molluscs, 
and insects (see Discussion). 
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PhyML 3.0 was then used to assemble an evolutionary tree of the key region of ERRs and 
steroid-type NRs in the vertebrate lineage. As shown in Figure 3, this confirms the presence 
of a candidate palmitoylation sequence in the inferred ancestral steroid receptor (AncSR, 
equating to AncSR1 of Thornton et al. [11]), and in all present day ERs, as well as in AR, GR, 
and PR – but in none of the ERR-like receptors. This conclusion is reinforced by computer 
prediction of palmitoylation sites (Figure S4). Although the key cysteine is absent from MR, 
the tree demonstrates that representatives of antecedents to present-day MR, including 
AncSR, all contain candidate palmitoylation sequences, confirming that this motif was lost 
from MR in more recent evolution. 
This analysis establishes a clear line of demarcation between the ancestral ERR and modern-
day steroid receptors. The demarcation line is only blurred by MRs, where the lipidation 
sequence appears to have been lost later in evolution. 
3.2. Molecular modeling – palmitate binds to a groove in the surface of ERα 
To address the localization of the palmitate moiety with respect to receptor structure we 
performed molecular modeling. The ERα ligand-binding domain was manually palmitoylated 
on Cys447, a molecular dynamics production run of 300 ns was performed, and the results 
analyzed using the VMD molecular dynamics program. The simulation trajectory reveals two 
distinct conformations for the hydrophobic palmitoyl group, both of which are partially 
buried among hydrophobic residues of the protein (Figure 4). Throughout the first 38 ns the 
palmitoyl group showed a stable conformation within a tunnel leading to the E2 binding site 
(conformation 1, Figure 4A). After a short transition conformation in which the lipid chain is 
bent back upon itself, a second, more stable conformation was adopted, pointing away from 
the E2 binding site (conformation 2, Figure 4B), in which the fatty-acyl moiety resides within 
a groove in the surface of the receptor.  
Because previous biochemical data indicate that E2 itself may bind to a second site within 
ERα in the vicinity of Cys447 [41], we performed molecular docking studies on the groove 
identified by palmitate binding. Autodock successfully reproduced the crystallographic 
binding mode of E2 to the ligand-binding site of ERα, with an RMSD from the 
crystallographic binding pose of 0.52 Å and a predicted G of −10.1  kcal/mol (estimated Kd = 
39.3 nM). Using the same protocol, E2 was docked into the putative second binding site, 
with the docking grid box centered on the palmitoyl chain in conformation 2 (Figure 4C). The 
G of this second binding site was predicted by Autodock to be −7.59 kcal/mol (estimated Kd 
= 2.8 M; ca 70-fold lower affinity), significantly weaker than the primary site. Key contact 
residues for palmitate and E2 (second-site) in the ERα ligand-binding domain are given in 
Table S6 and Figure S6. 
3.2. Metal binding 
In addition, it has been reported that Cys447 may participate in binding of physiological 
(Ca2+) and environmental (e.g., Cd2+) metals ('metalloestrogens') [42-44]. To address this we 
performed computational modeling, and a potential calcium binding site was identified 
sandwiched between helices H2, H8, and H9 of the ligand-binding domain of ERα. In Figure 
S7 the binding site is formed by the side chains of Cys447, Glu443, and Glu444 from H8, and 
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the backbone of H9. It is presumed that the site becomes solvent-accessible upon the same 
conformational changes that allow palmitoylation on 447; movement of H9 away from H8 to 
allow solvent access is also seen during the MD simulation. 
4. Discussion 
We report that the presence of a target sequence for lipidation in H8 accurately demarcates 
AncSR, ERs, and 3-ketosteroid receptors from the ERRs. This raises the question of whether 
lipidation sequences might have contributed to the emergence of AncSR from precursors.  
Extant ERRs appear to be largely defective in ligand-dependent modulation of transcriptional 
activation, and are thought to be ligand-independent receptors (e.g., [45]). Mammalian ERRs 
(ESRRA, ESRRB, and ESRRG) do not bind E2; indeed, the LBPs of ESRRA and ESRRG [13;16] are 
significantly smaller than those found in ERs, potentially ruling out ligand-activated 
transcription by the ERRs. However, ligand-dependent transcriptional activation (or 
inhibition) of ERRs has been reported for both synthetic and natural ligands, but in all cases 
high, and ostensibly non-physiological, concentrations were required [46-50], with the 
possible exception of cholesterol as a potential natural ligand for ERRγ [50]. Although this 
situation could change if further studies uncover natural high-affinity ligands for the ERR 
group of receptors, the exquisite sensitivity of, for example, ERα for E2, with half-maximal 
activation at below 1 nM (possibly as low as ~50 pM), so far appears to be lacking in extant 
ERRs.  
Together, these findings indicate that the ERRs inherently contain structural mechanisms for 
ligand-modulated transcription, but that the ligand-binding domain is constrained compared 
to the corresponding domain in steroid-type receptors, limiting physiological ligand-
dependent activation of the receptor. The emergence of a fatty-acylation site in the ligand-
binding domain of an ancestral ER could have accompanied changes in receptor structure 
that permitted high-affinity binding and transcription activation by E2, but the mechanism 
remains unclear. In the following we discuss (i) evolutionary antecedents, (ii) membrane 
localization as a potential contributor to the evolution of ERs, and (iii) the possibility of 
alternative ligands for the key cysteine residue. 
4.1. Evolutionary antecedents 
4.1.1. Amphioxus 
Amphioxus denotes an early branch of the chordate lineage that radiated prior to the 
emergence of the vertebrates. Two vertebrate-like steroid receptors are present in 
Branchiostoma floridae (the Florida lancelet), and both BfER and BfSR contain the key H8 
cysteine residue, whereas the BfERR lacks this residue (Figure 1). While BfER was not 
activated by any steroid tested (including E2, although binding to bisphenol A was reported) 
[51], BfSR was activated by both E2 and estrone at near-micromolar concentrations [52], a 
finding reiterated in the Japanese lancelet, Branchiostoma belcheri [53]. The lack of E2 
activation of BfER is puzzling. Nonetheless, both BfSR and BfER harbor sequence features of 
both ERRs and SRs; for example, they retain the indel at 496–498 that is characteristic of 
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ERRs (Figure S3), and thus appear to represent an intermediate step between ERRs and 
vertebrate steroid-type receptors. 
4.1.2. Insects, annelids, molluscs 
Although our study focuses on the vertebrate lineage, several more distant members of the 
Bilateria [a group that includes both protosomes (e.g., nematodes, arthropods, and molluscs) 
and deuterostomes (e.g., vertebrates and echinoderms)], notably annelids, harbor both ERR-
like receptors as well as a separate group of receptors, classifed as NR3D [10], that are 
reported to respond to E2 (see below). This prompted us to look wider. 
In insects, where receptor activation by E2 has not been reported, BLAST searching with 
human ERα revealed that all close relatives (top 100 BLAST hits for the human ESR1 ligand-
binding domain) lack a cysteine residue at the corresponding position, with the exception of 
some RXR-like receptors, a finding that might be fortuitous. 
For molluscs (e.g., clams, oysters, snails, and octopi) the cysteine residue was also absent 
from polypeptides most closely related to human ERα (ESR1 ligand-binding domain BLAST 
search). NR3D receptors of molluscs have been reported to be constitutively active receptors 
[54], and thus resemble the ERRs. 
In annelids (segmented worms), by contrast, there has been a report that NR3Ds from 
Platynereis dumerilii and Capitella capitata are capable of E2- (and estrone)-mediated 
transcription activation, but not by other steroids [55]. All close relatives (human ESR1 
ligand-binding domain BLAST search) were found to lack the H8 cysteine residue. 
Phylogenetic analysis (PhyMl) indicated that two NR3D receptors (from Mytilus edulis, the 
blue mussel, and Mytilus galloprovincialis, the Mediterranean mussel) are closely related to 
the vertebrate ERR group of receptors, whereas the remaining NR3D polypeptides appeared 
to be more closely related to the vertebrate ER group, although constituting a distinct 
group(s) on their own (Figure S8). Nevertheless, phylogenies based on block sequence 
comparisons risk overlooking complexities such as subdomain motif exchanges (e.g., taking 
place by exon swapping or gene conversion). Moreover, the evolutionary ancestry of the 
annelid and mollusc receptors has been hotly debated (e.g., [10;56;57]), and the E2-
responsive NR3D receptors of these species may possibly have an evolutionary origin that is 
distinct from vertebrate steroid-type receptors. Of note, the concentration of E2 necessary 
to activate the annelid NR3D receptors (ca 0.1 micromolar) contrasts with the sub-
nanomolar concentrations of E2 that activate vertebrate ERs. 
4.2. Palmitoylation and receptor function 
The presence of a candidate lipidation sequence in vertebrate steroid-type receptors, but 
not in their evolutionary precursors represented by extant ERRs, invites consideration of the 
potential role of lipidation in receptor function. It is increasingly recognized that NRs can 
associate with membranes, where they can mediate fast non-genomic signaling ('MISS' [1]). 
Palmitoylation is thought to be an essential step in routing NRs to membranes. 
Palmitoylation is necessary for binding to caveolin (CAV1, itself a palmitoylated protein) that 
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in turn promotes shuttling of ERα to the membrane [22;58], and mutation of Cys447 in ERα 
abolished both membrane association and ERK activation [21;59].  
However, palmitoylation is a dynamic modification, and cycles of 
palmitoylation/depalmitoylation are fundamental to signaling by some receptors (reviewed 
in [20]). In the case of the ER it has been suggested that E2 binding promotes removal of the 
covalently bound lipid, releasing the receptor from membranes and facilitating gene 
expression through receptor-mediated transactivation in the nucleus, thereby providing an 
additional ON–OFF toggle for ligand-dependent activation of transcription ([21;59]; reviewed 
in [1]). For these reasons, loss of membrane association per se is unlikely to explain the 
defects in E2-mediated gene expression seen in receptor mutants (or indeed in evolutionary 
antecedents) lacking the key cysteine residue.  
Nevertheless, in a key paper, Reese and Katzenellenbogen [17] demonstrated that mutation 
of the palmitoylation site in ERα strongly impaired ligand-dependent transactivation, but that 
the block in the non-palmitoylated receptor could be overcome by a 50-fold excess of ligand. 
This indicates that there is a structural deficiency in the non-fatty-acylated receptor that may 
be overcome by either excess ligand or, plausibly, by the addition of a covalently attached 
long-chain fatty acid. Other studies concur that the key target cysteine residue in ERα plays a 
role in determining the higher-order structure of the ligand-binding domain and hormone-
dependent activation of transcription [60;61]. In confirmation, mutation of the target 
cysteine residue in vivo in mouse ERα led to complete female infertility and downregulation 
of E2-responsive gene expression [23;24]. 
The finding that mutation of the key cysteine residue in ERα markedly reduces 
transcriptional activation (50-fold) without a major effect on E2 binding affinity (at best 
twofold), and that the defect can be overcome by a 50-fold excess of ligand [17], is 
nevertheless perplexing. Several explanations may be offered, such as deficits in coactivator 
binding (that was reported for this region of the ligand-binding domain in ERRα [14]) or in 
receptor dimerization [61], but this would not easily explain how the defect in ERα can be 
overcome by excess E2. By contrast, the observation is consistent with the possibility that 
two (or more) hydrophobic binding sites are present in the ligand-binding domain.  
In support, it has been known for many decades that fatty acids can modulate NR function, 
including ER, GR, and PR, depending on their concentration, length, and degree of 
unsaturation, but do not compete with steroidal ligands targeting the LBP [62-66], pointing 
to a second interaction site that has not been firmly identified. In addition to fatty acids, to 
explain the curious pharmacologic behavior of antiestrogens, it has long been speculated 
that there may be one or more secondary binding sites on the estrogen receptor for 
steroidal ligands that do not compete with E2 for binding [67-73]; indeed, there may be 
several secondary sites [74]. 
Importantly, biochemical evidence indicates that the key target residue Cys447 of E. coli-
produced ERα ligand-binding domain (lacking palmitoylation) immobilized on an E2 affinity 
column does not react with iodoacetic acid, whereas the free denatured protein reacted 
readily with iodoacetic acid at this site [41]; the authors argued that ligand binding in the 
vicinity of Cys447 (a site distal from the E2 LBP) restricts access to this specific residue. 
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Although the possibility that the affinity resin (sepharose) masks iodoacetic acid from 
interacting with Cys447 was not formally excluded, this would require hydrophilic contacts 
with a predominantly hydrophobic region of the ligand-binding domain. Our molecular 
dynamics and docking studies indicate that both palmitate and excess E2 may occupy a 
second hydrophobic pocket in the vicinity of H8 of the ERα ligand-binding domain. The target 
cysteine is within 4 Å of E2 (Table S6 and Figure S6), and E2 bound to this site could therefore 
mask Cys447 from chemical modification, as proposed [41]. 
The accumulated data thus suggest that covalent addition of a long-chain fatty acid to a 
hydrophobic site in the vicinity of H8 (or ligand excess) may lead to a change in receptor 
structure/interactions that facilitate transactivation mediated by ligand binding within the 
conventional LBP. The model could explain why some studies on Cys447 mutants of ERα did 
not detect significant downregulation of receptor activity at high (up to micromolar) ligand 
concentrations [21;59;61]. Nevertheless, the physiological relevance of E2 binding to this site 
is open to question. In addition to the supra-physiological ligand concentrations required, the 
17β and 3β hydroxyl groups of E2 appear only to participate in binding to the second site via 
hydrogen bonding with the backbone (C3 hydroxyl to Leu310 oxygen, 2.7 Å; and C17 hydroxyl 
to Ile482 oxygen, 3.2 Å; supplementary data online): although (physiological) second-site 
ligands other than E2 are not excluded, E2 binding may take place fortuitously to a site built 
to accommodate a uniformly hydrophobic molecule such as palmitate. 
By contrast, covalent addition of palmitate might radically change the dynamics of the 
interaction. Occupancy of the hydrophobic site close to H8 by covalently bound palmitate 
could stabilize a new conformation change or secondary interaction that promotes receptor 
activity in response to ligand binding to the conventional LBP. The acquisition of a lipidation 
target sequence in H8 of vertebrate NRs could thus have contributed to the emergence of 
steroid receptors capable of responding to sub-nanomolar concentrations of steroidal ligands. 
No crystal structure is so far available for NRs covalently modified by long-chain fatty 
acylation; however, if this technical obstacle can be overcome, it would be of great interest to 
explore to what extent this modification affects the overall structure of the ligand-binding 
domain. Further, it would be of great interest to determine whether addition of a 
palmitoylation sequence to ERRs, in conjunction with modifications to the LBP, might 
together generate a steroid-type receptor capable of responding to low (picomolar) 
concentrations of ligand. Equally, whether reintroduction of the missing cysteine motif into 
MR would have repercussions for ligand affinity or transcriptional activity. 
4.3. Is there an alternative ligand for Cys447? 
Although Cys447 is undoubtedly required for full receptor activity in vivo, and is a target for 
palmitoylation, there are some caveats. First, there is so far no evidence that palmitoylated 
receptors can enter the nucleus to activate transcription. Second, the inference that the key 
cysteine residue might undergo multiple cycles of palmitoylation and depalmitoylation is 
somewhat inconsistent with the fact that Cys447 is not well exposed at the surface (e.g., 
Figure 4), and might only be available to palmitoylation enzymes co-translationally. Third, in 
many cells only 5–10% of ER is palmitoylated and targeted to the cell membrane ([75] for 
review), and thus in these cells the key cysteine residue is largely free for other interactions. 
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We therefore considered whether the major population of ER (lacking palmitoylation) might 
have other binding partners. 
Metal ions are candidate ligands for Cys447 because both physiological and environmental 
metals (metalloestrogens) are known to activate ER with high affinity (nM), and Cys447 has 
been specifically implicated. Environmental metals such as Cd2+ are known to exert adverse 
estrogenic effects across a range of vertebrate species by binding to the ligand-binding 
domain of ER [42-44;76]. Activation extends to physiological metals such as calcium that can 
modulate ER activity in vivo: extracellular Ca2+ increased the growth of MCF-7 cells via an ER-
dependent mechanism, and chelation of Ca2+ blocked ERα activity [77]. Although not widely 
studied except in mammals, in addition to ERα and ERβ, heavy metals have been reported to 
interact with AR [78], GR [42;79;80], and PR [81]. 
In vertebrate ER the site(s) for metal binding in the LBD are distinct from the hormone-
binding pocket, and several Cys, His, Asp, and Glu residues (including Cys447, Cys381, Glu523, 
His524, and Asp538) have been implicated as potential candidate interaction sites [42-44]. 
Significantly, mutation of Cys447 abolished metal-mediated receptor activation [42;43] 
indicating that, in addition to lipidation, this residue may be functionally liganded by 
physiological metals such as Ca2+. In support, molecular modeling (Figure S7) indicates that 
Cys447, in conjunction with Glu443 and Glu44 in human ESR1, presents a potential binding 
site for Ca2+ binding. The two glutamate residues at 443 and 444 are substantially conserved 
throughout this group of receptors (Figure S3).  
We note that Cys447 is not the only potential metal-reactive residue that differs between SRs 
and ERRs, and the evolution of SRs is accompanied not only by the emergence of Cys447 but 
also by loss of a cysteine residue corresponding to Thr347 in human ESR1 (Figure S3), 
suggestive of a switching process rather than merely the emergence of Cys447. No 
systematic work appears to have been done on metals and ERRs, nor on related receptors in 
more distant taxa including annelids and molluscs; further studies will be necessary to 
investigate whether, in addition to palmitoylation, metal binding might distinguish between 
steroid-type receptors and their evolutionary antecedents. 
In sum, our finding that the key cysteine motif in H8 is present in vertebrate steroid receptors, 
but in none of their evolutionary antecedents, the ERRs, highlights the potential importance 
of the H8 region in the evolution of SRs, and concurs with several reports that this region 
plays a vital role in modulating the 3D structure of extant NRs [14;17;61;82]. Although it 
remains uncertain whether lipidation is the only ligand for the key cysteine residue, our 
findings corroborate the suggestion by Greschik et al. that this region of the protein could 
serve as an alternative to the LBP for the design of small-molecule drugs [14].  
5. Conclusions 
The molecular changes that led to the emergence of the first vertebrate steroid receptors 
are not yet understood. We report here a striking line of demarcation between vertebrate 
steroid receptors and ERRs, in that the former contain a conserved lipidation sequence that 
is entirely absent from the latter. This change could have accompanied the evolution of 
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steroid receptors from their inferred ancestor, AncERR, that give rise to both ERRs and 
steroid receptors. 
There are many uncertainties: (i) although confirmed for ERα, ERβ, PR, and AR, it has not 
been formally demonstrated that this consensus sequence directs fatty-acylation across the 
spectrum of vertebrate NRs, and studies on the earliest representatives such as amphioxus 
ERR versus ER/SR or related species would be informative; and also (ii) it may not be 
assumed that the key cysteine residue (that is absent in ERR but present in steroid-type 
receptors) only guided lipidation, and it could be a target for an alternative physiological 
ligand such as metal ions (e.g., Ca2+) or possibly fatty acids/sterols, or play another role so far 
unknown. Furthermore, (iii) evolution of SRs from AncERR undoubtedly proceeded through a 
progressive series of steps, and the emergence of the key cysteine residue is likely to 
represent only one of multiple modifications that led to modern-day vertebrate steroid-type 
receptors. 
Nevertheless, given that the key H8 cysteine residue in the ligand-binding domain accurately 
demarcates extant steroid-type NRs from the ERRs, and that the lipid attachment site has 
been implicated in remodeling of receptor structure to facilitate transcriptional activation at 
low ligand concentrations, close scrutiny of the evolutionary and structural correlations 
between lipidation (and potentially metal binding) and NR evolution could shed light on the 
key changes that led to the emergence of steroid signaling in vertebrates. 
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Figure 1. Color-coded alignment (simplified) of the central α-helix (H8) and flanking residues 
(435–465) in the ligand-binding domain of selected estrogen-related receptors (ERRs) and 
vertebrate receptors responding to steroids (SRs). Numbering corresponds to human ERα 
(ESR1). The cysteine residue that is absent from all ERRs, but present in SRs, is indicated (*, 
corresponding to Cys447 in human ERα). Extended alignments are presented in Figures S2 
and S3. ERRs are presented in approximate evolutionary order, whereas SRs are presented in 
reverse order. Alignment display was performed using mView 
(www.ebi.ac.uk/Tools/msa/myview/) using default settings (color = 'Any'; yellow, Cys; red, 
Arg/Lys; dark blue, Asp/Glu; light blue, Ser/Thr; dark green, Phe/Tyr/Trp/His; purple, 
Gln/Asn; lighter green, other – Gly/Ala/Pro/Leu/Ile/Val/Met). Species names (prefixes): Bf, 
amphioxus, Branchiostoma floridae; Dr, zebrafish, Danio rerio; Gg, chicken, Gallus gallus 
domesticus; h, human; Rt, shark, Rhincodon typus; Xl, Xenopus laevis. Abbreviations: ER/ESR, 
estrogen receptor; ERR/ESRR, estrogen-related receptor; SR, steroid receptor. 
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Figure 2. Palmitoylation sequences demarcate steroid-type nuclear receptors (red, 
containing the palmitoylation sequence) from precursor ERR (estrogen-related receptor) 
proteins (blue, that lack the key cysteine residue). Loss of the key cysteine residue in extant 
MRs appears to be a recent event. Species names (prefixes): Bf, amphioxus, Branchiostoma 
floridae; Ci, sea squirt, Ciona intestinalis; Dm, fruitfly, Drosophila melanogaster; Dr, zebrafish, 
Danio rerio; Gg, chicken, Gallus gallus domesticus; Hs, human; Pm, lamprey, Petromyzon 
marinus; Rt, shark, Rhincodon typus; Sp, sea urchin, Strongylocentrotus purpuratus; Xl, 
Xenopus laevis. Abbreviations. ESRR, vertebrate estrogen-related receptor; ER/ESR, estrogen 
receptor; AR, GR, MR, PR, androgen-, glucocorticoid-, mineralocorticoid-, and progesterone-
type receptors, respectively; CR, lamprey corticosteroid-related receptor; SR, amphioxus 
(cortico)steroid-related receptor. 
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Figure 3. Phylogenetic analysis of the ligand-binding domains of estrogen-related (ERR) and 
steroid-type nuclear receptors (NRs). Loss of the lipidation target site is a recent event in the 
evolution of MRs (text for discussion). Sequences analyzed were 58 residues in length, from 
26 residues before the key cysteine residue (or equivalent) to 31 residues following it; the 
identical tree was generated using the complete ligand-binding domains, 547 residues, of 
these receptors (sequences in Figure S3 in the supplementary material online). Phylogeny 
employed PhyML 3.0 (http://www.atgc-montpellier.fr/phyml); tree drawing was with FigTree 
(http://tree.bio.ed.ac.uk/software/figtree). Line length reflects the number of sequences 
(fewer ERRs in this analysis than steroid-type NRs), and not their evolutionary relatedness. 
Species names (prefixes): Am/Ao, clownfish, Amphiprion melanopus/ocellaris; Bf, amphioxus, 
Branchiostoma floridae; Dr, zebrafish, Danio rerio; Gg, chicken, Gallus gallus domesticus; h, 
human; Pm, lamprey, Petromyzon marinus; Rt, shark, Rhincodon typus; Xl, Xenopus laevis. 
PhyML identified ERR sequences from fruitfly, Drosophila melanogaster, sea squirt (Ciona 
intestinalis), and sea urchin (Strongylocentrotus purpuratus) as outliers (not presented) and 
these were therefore omitted from the tree. Abbreviations. AncERR, inferred ancestral ERR; 
AncSR, inferred ancestral steroid receptor (see Introduction); ESRR, vertebrate estrogen-
related receptor; ER/ESR, estrogen receptor. AR, GR, MR, PR, androgen-, glucocorticoid-, 
mineralocorticoid-, and progesterone-type receptors, respectively; CR, lamprey 
corticosteroid-related receptor; SR, amphioxus (cortico)steroid-related receptor. 
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Figure 4. Molecular modeling, dynamics, and docking studies of the human ERα ligand-
binding domain. (A) Manually built energy-minimized model of ERα palmitoylated (grey) on 
Cys447 in H8 (conformation 1). The protein secondary structure is shown as helices (red), 
sheets (yellow), and strands (green), the palmitoyl group as CPK-colored spheres, and 
sidechains within 4 Ǻ of the lipid are shown as black lines. Estradiol (E2) is in light blue. (B) 
Conformation of the protein and palmitoyl group after 300 ns of molecular dynamics 
simulation (conformation 2). The palmitoyl group is now buried in a hydrophobic residue-
lined groove, pointing away from the primary E2 binding site. (C) Result of docking E2 into 
the putative second binding pocket adjacent to helix 8. Larger versions of these figures are 
provided in Figure S5 in the supplementary material online. 
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